Delving into the Latest Updates on Mesenchymal stem cell therapy (Stemedica Cell Technologies) with Synapse

Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

The main objective of the CIRCULATE project is to compare the clinical outcomes of CardioCell administration in treatment of ischemic damages of cardiovascular system with control group, who will be treated by the administration of placebo during the sham procedure.

Start Date19 Apr 2018

Sponsor / Collaborator

John Paul II Hospital, Krakow

[+2]

NCT02833792 / RecruitingPhase 2

A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease

STUDY OBJECTIVES
Primary:
To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease.
Secondary:
To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.

Start Date01 Jun 2016

Sponsor / Collaborator

Stemedica Cell Technologies, Inc.

[+1]

100 Clinical Results associated with Mesenchymal stem cell therapy (Stemedica Cell Technologies)

Login to view more data

100 Translational Medicine associated with Mesenchymal stem cell therapy (Stemedica Cell Technologies)

Login to view more data

100 Patents (Medical) associated with Mesenchymal stem cell therapy (Stemedica Cell Technologies)

Login to view more data

2

Literatures (Medical) associated with Mesenchymal stem cell therapy (Stemedica Cell Technologies)

01 Dec 2022·Research in Veterinary Science

Clinical status and endoscopy of the upper respiratory tract of dairy calves infected with Bovine viral diarrhea virus 2 and Bovine herpes virus 1 after vaccination and trace minerals injection

Article

Author: Divers, S J ; Bittar, J H ; Hoyos-Jaramillo, A ; Kirks, S J ; Palomares, R A ; Gonzalez-Altamiranda, E A ; Edmondson, M ; Chamorro, M F ; Rush, J ; Berghaus, R ; Rodriguez, A

The objective was to compare clinical protection [evaluated through health scoring, endoscopy score of the upper respiratory tract (URT-ES), leukocyte count, viremia, and virus shedding in nasal secretions] following Bovine viral diarrhea virus 2 (BVDV2) and Bovine herpes virus 1 (BHV1) challenge among calves submitted to modified-live virus (MLV) booster vaccination (either intranasal or subcutaneous) concurrent with injectable trace minerals (ITM) or saline. Forty-eight dairy calves received an MLV intranasal (IN) vaccine containing BHV1, BRSV, and BPI₃V and subcutaneous (SC) ITM (Se, Cu, Zn & Mn; ITM, n = 24) or saline (SAL, n = 24). Ten weeks later, calves received a second dose of ITM, or saline, according to previous groups and were randomly assigned to receive the same IN vaccine [ITM-IN (n = 12), SAL-IN (n = 12)] or a SC MLV vaccine containing BHV1, BRSV, BPI3V, BVDV1 & 2 [ITM-SC (n = 12), SAL-SC (n = 12)]. Additionally, 12 calves did not receive vaccine or treatment and served as a control group (UNVAC, n = 12). Forty-nine days after booster, calves were challenged with BVDV2; and seven days later with BHV1. Health scores indicated disease in UNVAC on days 6, 10 and 12 compared to the vaccinated groups. Unvaccinated calves had the highest URT-ES after BHV1 challenge. Calves that received SC booster had lower URT-ES after BHV1 challenge than UNVAC calves. Calves in ITM-IN had significantly lower URT-ES after BHV1 infection than SAL-IN and UNVAC calves. In conclusion, IN or SC MLV vaccination was similarly effective in protecting calves from BVDV2 + BHV1 challenges (reducing clinical and endoscopy scores, preventing leukopenia, and viremia), compared to unvaccinated calves. Endoscopic evaluation of the URT allowed visualization of the inflammation and damage at multiple depths in the URT caused by a serial BVDV2 + BHV1 challenge. Calves that received SC vaccination had significantly lower URT-ES after BHV1 challenge than the UNVAC calves. Administration of ITM concurrent with IN vaccination was associated with reduced URT inflammation after BVDV2 + BHV1 challenge.

20 Jan 2017·Circulation ResearchQ1 · MEDICINE

Safety and Efficacy Results of a Phase II-A Randomized Trial

Q1 · MEDICINE

Article

Author: Skopicki, Hal A. ; Gheorghiade, Mihai ; Ko, Yi-An ; Kim, Raymond J. ; Anderson, Allen S. ; Cole, Robert T. ; Epstein, Stephen E. ; Wilcox, Jane E. ; Tankovich, Nikolai I. ; Greene, Stephen J. ; Sikora, Sergey ; Butler, Javed ; Margulies, Kenneth B. ; Lipinski, Michael J. ; Quyyumi, Arshed A.

Rationale:Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role.Objective:To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy.Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction ≤40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5×10 6 cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98–66.97; P =0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70–9.74; P =0.02) and functional status scores (+5.65, 95% confidence interval −0.11 to 11.41; P =0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions:In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02467387.

100 Deals associated with Mesenchymal stem cell therapy (Stemedica Cell Technologies)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic stroke	Phase 3	US	Stemedica Cell Technologies, Inc.	19 Jan 2023
Skin aging	Phase 2	US	Stemedica Cell Technologies, Inc.	01 Jul 2015
Diabetic Retinopathy	Phase 2	RU	Fyodorov Eye Microsurgery Complex	-
Myocardial Infarction	Phase 2	US	Cardiocell LLC	-
Diabetic Retinopathy	Preclinical	RU	Stemedica Cell Technologies, Inc.	-
Lung Diseases	Preclinical	US	Pulthera	-
Lung Diseases	Preclinical	US	Stemedica Cell Technologies, Inc.	-
Dementia	Discovery	US	Stemedica Cell Technologies, Inc.	03 Jul 2016
Heart Failure	Discovery	MX	Stemedica Cell Technologies, Inc.	12 Feb 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02467387 (Pubmed \| Circulation) Manual	Phase 2	Cardiomyopathies	22	itMSC	(dzxbizpjym) = cuglrsbwpi fodpmpaflb (ubiucflkhp, 5.98 ~ 66.97) View more	Positive	20 Jan 2017
				Placebo	-